Cite

HARVARD Citation

    Wollenberg, A. et al. (2020). Assessing the need for routine safety testing for patients being treated with dupilumab for moderate‐to‐severe atopic dermatitis. British journal of dermatology. p. e186. [Online]. 
  
Back to record